CME Policy on Full Disclosure
The Alberta Psychiatric Association requires disclosure of the existence of ANY AND ALL financial interest(s) or other affiliation(s) a presenter has with commercial supporter(s) of these educational activities, and/or with manufacturer(s) of ANY AND ALL commercial product(s) and/or provider(s) of ANY AND ALL commercial services discussed in the scientific program. The existence of such relationships does not necessarily constitute a conflict of interest, but the prospective audience must be informed of the presenter’s affiliation with every commercial sponsor by way of an acknowledgement in program.
This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own opinions about the presentation. A reasonable test to guide decisions about what to disclose is whether any particular affiliation could cause embarrassment to the individual or institution involved or lead to questions about the presenter’s motives if such affiliation(s) were made known to the general public.
The following presenters have indicated a financial interest or other affiliation with a commercial supporter of the session and/or with the manufacturer(s) of a commercial product and/or provider of commercial service(s):
| Speaker | Co-Author | Affiliation |
| Christoph Correll |
AbbVie, Acadia, Adock Ingram, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Eli Lilly, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, Kuleon Biosciences, LB Pharma, Lundbeck, MedInCell, MedLink, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, PPD Biotech, Quantic, Recordati, Relmada, Reviva, Rovi, Sage, Saladax, Sanofi, Seqirus, SK Life Science, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Terran, Tolmar, Vertex, Viatris and Xenon Pharmaceuticals |
|
| Cassandra Felske-Durksen |
Alberta Medical Association Indigenous Health Committee - Chair |
|
| Deena Hinshaw |
Employee of the Government of Alberta, Jan 2019 to Nov 2022 (salaried) Clinical faculty appointment in the Division of Preventive Medicine, Department of Medicine, School of Medicine and Dentistry, University of Alberta, July 2010 to present (no financial compensation) Contract work with the Government of British Columbia, Jan 2023 to Oct 2023 (hourly rate compensation) Employee of the Government of Canada, Indigenous Services Canada, Jan 2024 to present (salaried) |
|
| Zayna Khayat |
University of Toronto - adjunct faculty; Deloitte Canada - contractor; Talk Boutique - member of speaker's bureau; Teladoc Health Canada - contractor; Santis Health - expert advisor and I2U advisory board; Kudos - expert advisor; CADTH (Canadian Drug Agency) - expert advisor and AI advisory panel; PHAC - Type 2 Diabetes Challenge advisory panel PHSA (BC) - contractor Canada School of Policy - guest lecturer / contractor Rotman School of Management - Health Leadership Advisory Board |
|
| Candice Monson | CIHR, Nellie Health | |
| Ric Procyshyn | AbbVie, Eisai, HLS, Janssen, Lundbeck, Otsuka |